Despite the newly developed oral antiviral treatments, pegylated interferon (PEG IFN) alpha still has an important place in the treatment of chronic hepatitis C in many countries and in the treatment of chronic hepatitis B in selected cases. Pegylated interferons have certain side effects, primarily flu-like symptoms, myalgia, fatigue, gastrointestinal disorders, psychiatric disorders, and hematological disorders.
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There was a decrease in the restrictive pattern and diffusing capacity in the pulmonary function tests. Infectious etiology was not detected in culture and broncho alveolar lavage fluid analyses. It was thought that the current situation of the patient is interstitial pneumonia due to the use of IFN. The treatment was ceased and the patient started to be monitored. The clinical condition of the patient gradually improved after the discontinuation of the treatment. Hepatitis C recurrence was observed in the follow-up; however, significant lung symptom was not observed. Pulmonary toxicity is a rare condition observed in patients with HCV treated with the combination of PEG IFN and ribavirin. Interstitial pneumonia, bronchiolitis obliterans with organizing pneumonia (BOOP), pleuritis, sarcoidosis, and asthma exacerbations can be observed during combined treatment. 2, 3 Interstitial pneumonia is among the rare side effects of IFN alpha and reported as 0.4% in the study series. 4 Although it can occur at any phase of the treatment, it was generally observed in weeks 2 to 16 in the reported cases, and it generally manifests with dry cough and shortness of breath. 5 In the case reported by Atug et al, interstitial pneumonia findings were detected in the 36th week of the treatment. 6 Again in the literature, it was reported that interstitial pneumonia related to PEG IFN mostly improves with the discontinuation of the medicine; however, it was reported that it can also be unresponsive to treatment or with a fatal course. 5, 6 In our case, interstitial pneumonia emerged with the symptoms of dry cough and shortness of breath in the 28th week of the treatment, and it was observed that the findings improved with the discontinuation of the medicine. Although its mechanism is not precisely known, direct toxic effect of drug or cytotoxic T-cell activity and soluble IL-2 receptor, IL-18 binding proteins, platelet-derived growth factor, and immunomodulatory reactions, such as tumor growth factor-beta induction can help explain the effects observed. 7 Consequently, interstitial pneumonia should be taken into consideration in the differential diagnosis of the pulmonary symptoms that may occur during PEG IFN treatment. This rare complication can have a serious course and the treatment should be stopped when necessary. 
